Legal Representation
Attorney
Melanie Howard
USPTO Deadlines
Next Deadline
1220 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20190521)
Due Date
May 21, 2029
Grace Period Ends
November 21, 2029
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 21, 2025 | E815 | I | TEAS SECTION 8 & 15 RECEIVED | Loading... |
| May 21, 2024 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | Loading... |
| May 21, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 5, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 5, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 13, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jan 29, 2019 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
| Jan 25, 2019 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
| Jan 19, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 10, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 10, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 6, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Nov 30, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 23, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 23, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 23, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 23, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 20, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 16, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; pharmaceutical drugs and pharmaceutical substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; synthetic peptides for pharmaceutical use for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; vaccines
Class 042
Scientific research for medical purposes in the field of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases; pharmaceutical drug research and development services; medical research services; pharmacological research services in the nature of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the fields of pharmaceutical and clinical trials; conducting clinical trials for others; information, advisory and consultancy services relating to the aforesaid
Classification
International Classes
005
042